secwatch.observer — SEC 8-K summary
======================================

Issuer:     Day One Biopharmaceuticals, Inc. (—)
CIK:        0001845337
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053598
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Day One Biopharma Q1 net loss $62.4M, launches OJEMDA after April FDA approval
------------------------------------------------------------------------------

- Q1 2024 net loss $62.4M vs $42.4M YoY; cash $317.9M expected to fund ops into 2026.
- OJEMDA (tovorafenib) received FDA accelerated approval in April for relapsed/refractory BRAF-altered pLGG; first prescriptions written.
- R&D expenses $40.2M (up from $27.8M) driven by compensation, PRV buyback, and clinical activities.
- Phase 3 FIREFLY-2 front-line pLGG trial enrolling with >90 sites activated globally.
- Rare pediatric disease priority review voucher received upon OJEMDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/0000950170-24-053598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/dawn-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer